{
  "docId": "019de075-814d-76ed-b6e6-6e437a6b6631",
  "docSlug": "56480dbdf83cce5ae4f2fad948f0ee58",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 26 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 26,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines the methodology and endpoints of a clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-814d-76ed-b6e6-6e437a6b6631/10",
  "deckHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631",
  "deckJsonHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631.json",
  "deckAnchorHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.94,
        "x": 0.03,
        "y": 0.27
      },
      "kind": "list",
      "text": "Compared Sildenafil Cream vs. placebo used in patients' home setting.\nCo-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).\nSecondary endpoint: measured change in the number of satisfactory sexual events\nExploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e707e17-ca9b-4990-871c-3d06765c8d64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a non-drug and placebo run-in period",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88bf86d8-c037-4681-a6d4-330190a9bca6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.64,
        "x": 0.18,
        "y": 0.81
      },
      "kind": "paragraph",
      "text": "Topline data of exploratory Phase 2b RESPOND study announced June 5, 2023.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf8e0d70-6996-4133-aba9-fe003cc88874",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.07,
        "y": 0.04
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% - Phase 2b RESPOND Study - Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eb8ade7-c594-45a6-8d8c-3e5affa49e39",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "83faa245-7d21-49f3-aa4d-68f21da0e116",
      "evidence": "The deck presents the consequences of not addressing FSAD/FSIAD on pages 8-11",
      "position": 0,
      "objective": "Highlight the need for a treatment for FSAD/FSIAD",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}